US Stock Market Move | Pause patient dosing and screening for the phase III clinical trial of NEX-Z caused Intellia Therapeutics (NTLA.US) to plummet over 45%.
On Monday, Intellia Therapeutics (NTLA.US) plummeted over 45%, closing at $13.90.
On Monday, Intellia Therapeutics (NTLA.US) plummeted more than 45%, closing at $13.90. In terms of news, Intellia Therapeutics announced that it has paused patient dosing and screening activities in two Phase 3 clinical trials for nex-z. These trials are for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, as one patient reported a Grade 4 elevation in liver transaminases and an increase in total bilirubin after treatment. The patient has been hospitalized and is receiving medical intervention.
Intellia stated that they are consulting with experts and considering potential risk mitigation strategies, while also communicating with regulatory authorities with the goal of resuming trial recruitment as soon as appropriate.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
